Verana Health Introduces Qdata Explorer in Advance of 2024 American Academy of Ophthalmology Annual Meeting
09 oct. 2024 09h00 HE
|
Verana Health, Inc.
SAN FRANCISCO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Today, Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD),...
AAVantgarde announces first patient dosed in First-In-Human Phase 1/2 LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa related to Usher Syndrome type 1B
16 sept. 2024 02h00 HE
|
AAVantgarde Bio
AAVantgarde announces first patient dosed in First-In-Human Phase 1/2 LUCE-1 study
Retinitis Pigmentosa Clinical Trial Pipeline Insights Featuring 40+ Companies | DelveInsight
07 mai 2024 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, May 07, 2024 (GLOBE NEWSWIRE) -- Retinitis Pigmentosa Clinical Trial Pipeline Insights Featuring 40+ Companies | DelveInsight Retinitis pigmentosa is a genetic disorder characterized...
Retinitis Pigmentosa Market Size Expected to Reach USD 21.40 Bn by 2033
06 mai 2024 09h49 HE
|
Precedence Research
Ottawa, May 06, 2024 (GLOBE NEWSWIRE) -- The global retinitis pigmentosa market size was valued at USD 14.02 billion in 2023 and is predicted to hit around USD 19.90 billion by 2032, a study...
Nacuity Pharmaceuticals Announces Expansion of its Business Advisory Board with Appointment of Rare Disease Advocate Daniel Feller
14 févr. 2024 09h00 HE
|
Nacuity Pharmaceuticals, Inc.
FORT WORTH, Texas, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other...
Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024
14 févr. 2024 07h30 HE
|
Ocugen
Highlighting updates on OCU400 Phase 3 clinical trial starting early 2024 Featuring thought leaders in gene therapy and OCU400 Phase 1/2 clinical trial patient MALVERN, Pa., Feb. 14, 2024 ...
Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
13 sept. 2023 08h15 HE
|
Ocugen
Favorable safety and tolerability profile of OCU400 investigational drug product in RP and LCA subjects to dateClinical study update suggests continued positive trends in Best-Corrected Visual Acuity...
Nacuity Pharmaceuticals Achieves Target Enrollment for Phase 1/2 Clinical Trial of NPI-001 for the Treatment of Retinitis Pigmentosa Associated with Usher Syndrome
31 mai 2023 09h00 HE
|
Nacuity Pharmaceuticals, Inc.
Phase 1/2 SLO-RP trial completed target enrollment of 48 patients diagnosed with RP associated with USH Interim efficacy data anticipated by year end 2023 FORT WORTH, Texas, May 31, 2023 (GLOBE...
Coave Therapeutics announces Positive 12-months Data from Ongoing Phase I/II Clinical Trial of CTx-PDE6b in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b
31 mai 2023 06h00 HE
|
Coave Therapeutics
CTx-PDE6b demonstrated clinically meaningful benefit in visual functions at the highest dose and exhibits a good safety profile Positive results from the study to date support preparations for a...
Endogena Therapeutics Completes Enrollment Ahead of Schedule in its Phase 1/2a Trial of EA-2353 for Retinitis Pigmentosa
04 mai 2023 03h00 HE
|
Endogena
SAN FRANCISCO and TORONTO and ZÜRICH, Switzerland, May 04, 2023 (GLOBE NEWSWIRE) -- Endogena Therapeutics Inc., a clinical-stage biotech company, is pleased to announce that it has completed...